People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2025 |
| Agenus Inc | — | Biotechnology | Series C | $211.2M | $1.2B | 2009 |
| Precision Biosciences Inc | — | Biotechnology | Series C | $153.3M | $1.6B | 2019 |
| Mahzi Therapeutics Inc. | — | Biotechnology | Series C | $52.6M | $1.3B | 2021 |
Shalini Sharp at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shalini Sharp on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JEFF SMITH | 1 | 17 |
| Ben Auspitz | 1 | 9 |
| Jishnu Bhattacharjee | 1 | 9 |
| Timothy Wright | 1 | 7 |
| Camille Samuels | 1 | 6 |
| Robert Stein | 1 | 6 |
| R. Jacob Vogelstein | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Robert B. Stein | 1 | 5 |
| Robert Adelman | 1 | 5 |
| Thomas Miller | 1 | 5 |
| William Rastetter | 1 | 4 |
| Shahzad Malik | 1 | 4 |
| MATTHEW KANE | 1 | 4 |
| Marten Steen | 1 | 3 |
| Mary Tagliaferri | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Garo H. Armen | 1 | 3 |
| Shahzad M. Malik | 1 | 3 |
| Tony Yao | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.